PMC:7696151 / 86481-86809
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2539 | 233-241 | Species | denotes | patients | Tax:9606 |
| 2540 | 313-321 | Species | denotes | patients | Tax:9606 |
| 2557 | 29-32 | Chemical | denotes | HCQ | MESH:D006886 |
| 2558 | 117-127 | Chemical | denotes | everolimus | MESH:D000068338 |
| 2576 | 69-77 | Disease | denotes | toxicity | MESH:D064420 |
| 2577 | 201-232 | Disease | denotes | clear-cell renal cell carcinoma | MESH:C538614 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T215 | 201-232 | Phenotype | denotes | clear-cell renal cell carcinoma | http://purl.obolibrary.org/obo/HP_0006770 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T549 | 0-328 | Sentence | denotes | Likewise, doses of 600 mg of HCQ twice a day are not associated with toxicity and its usage as adjuvant therapy with everolimus was well tolerated and produced disease control in 67% of the metastatic clear-cell renal cell carcinoma patients and achieved the rate of six month progression-free survival in 45% of patients [170]. |